Former President and CEO · BIO-TECHNE Corp (TECH)

Charles Kummeth

A named executive officer of BIO-TECHNE in every fiscal year CompBrief holds from FY2016 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$6,792,945

Salary $1,184,200Stock awards $5,000,028

FY2023: $30,584,644

2nd of 6 named executive officers at BIO-Techne by FY2024 total.

6 named officers on file for BIO-TECHNE, FY2024

Charles Kummeth’s pay file — $29

  • 9 fiscal years of pay, line by line
  • 19 equity grants, each cited to its filing
  • TECH’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BIO-TECHNE’s whole pay program stands against its peers

  • BIO-TECHNE’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TECH→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed September 12, 2024 (DEF 14A).

Free

Get Charles Kummeth’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Charles Kummeth compensation by year

BIO-TECHNE Summary Compensation Table · all 9 fiscal years held
In US dollars, as BIO-TECHNE reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Salary$800,000$880,000$911,000$957,000$1,053,000$1,116,000$1,183,000$1,184,200$1,184,200
Bonus$0$0$0$0$0$0$0$0$0
Stock awards$2,500,044$3,550,140$3,550,008$3,999,925$4,310,652$4,599,864$5,149,692$5,000,108$5,000,028
Option awards$2,908,732$3,549,359$3,550,081$4,000,343$4,310,748$6,599,940$5,149,669$24,325,102$0
Non-equity incentive$1,221,097$1,053,594$1,610,925$2,008,183$1,767,957$3,537,214$3,856,735$54,092$596,837
Pension and deferred compensation$0$0$0$0$0$0$0$0$0
All other$38,241$43,798$42,860$45,688$41,425$36,879$31,452$21,141$11,880
Total$7,468,114$9,076,890$9,664,874$11,011,138$11,484,782$15,889,896$15,370,549$30,584,644$6,792,945

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIO-TECHNE Corp DEF 14A filed September 12, 2024, accession 0001308179-24-000703, and prior-year filings. Open the filing on EDGAR.

How this page was built: the BIO-TECHNE Corp filed document, accession 0001308179-24-000703. Every figure is read from that document and cited to the page and table it appears in. Filed September 12, 2024.

$7.5M
$9.1M
$9.7M
$11.0M
$11.5M
$15.9M
$15.4M
$30.6M
$6.8M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU59,095$4,234,157—
RSU35,268$2,526,952—
PSU32,064$2,297,386—
RSU7,124$510,435—
Option38,296—$66.97
Option41,752—$120.46
Option125,260—$120.46
Option600,000—$94.52

Per the Outstanding Equity Awards at Fiscal Year-End table in BIO-TECHNE Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

BIO-TECHNE’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Kim KeldermanPresident and CEO Former President, Diagnostics and Genomics$6,852,495
Charles Kummeth · this pageFormer President and CEO$6,792,945
James HippelExecutive Vice President and CFO$5,202,632
William GeistPresident, Protein Sciences$3,647,219
Matthew McManusPresident, Diagnostics and Genomics$1,994,642
Shane BohnenSenior Vice President and General Counsel$1,455,793

Board service

BIO-TECHNE board · FY2021–FY2023

How this board is paid

Company policy: BIO-TECHNE pays directors a $75,000 cash retainer and $200,000 in 50% stock options, 50% restricted stock. As stated in BIO-TECHNE's FY2023 proxy.

The full BIO-TECHNE compensation record

free company brief

This page is one person within BIO-TECHNE's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the BIO-TECHNE proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIO-TECHNE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Charles Kummeth's compensation dossier · One-time report. No refunds.